Subscribe to our Newsletters !!
Few developments in science and technology have be
In modern pharmaceutical and laboratory settings,
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceuticals Limited (Alembic) today an
2026 marks a new chapter for the pharmaceutical an
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Alembic Pharmaceuticals has gotten last endorsement from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxycycline Hyclate Tablets USP, 75 mg and 150 mg.
The endorsed ANDA is remedially proportional to the reference recorded medication item (RLD), Acticlate Tablets, 75 mg and 150 mg, of Almirall, LLC. Doxycycline Hyclate Tablets, 75 mg and 150 mg are demonstrated for the treatment of certain Rickettsial, explicitly transmitted, respiratory tract, bacterial and ophthalmic contaminations.
It is likewise shown for Bacillus anthracis including inward breath Bacillus anthracis. It is demonstrated as an elective treatment for specific diseases where Penicillin is contraindicated. It is likewise demonstrated as an adjunctive treatment for intense intestinal amebiasis and extreme skin break out and for prophylaxis of jungle fever.
Doxycycline Hyclate Tablets USP, 75 mg and 150 mg have an expected market size of US$ 17 million for a year finishing March 2020 as per IQVIA.
Alembic presently has an aggregate of 125 ANDA endorsements (111 last endorsements and 14 provisional endorsements) from USFDA.
